AVITA Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference
AVITA Medical (NASDAQ: RCEL), a regenerative medicine company specializing in wound care management and skin restoration devices, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Jim Corbett will deliver a presentation on Thursday, January 16, 2025, at 9:00 a.m. Pacific Time. The presentation will be available via live audio webcast on the company's investor relations website, with a replay option available after the event concludes.
AVITA Medical (NASDAQ: RCEL), un'azienda di medicina rigenerativa specializzata nella gestione delle ferite e nei dispositivi per il ripristino della pelle, ha annunciato la sua partecipazione al 43掳 Annuale J.P. Morgan Healthcare Conference. Il CEO Jim Corbett terr脿 una presentazione gioved矛 16 gennaio 2025, alle 9:00 ora del Pacifico. La presentazione sar脿 disponibile tramite webcast audio dal vivo sul sito delle relazioni con gli investitori dell'azienda, con un'opzione di riproduzione disponibile dopo la conclusione dell'evento.
AVITA Medical (NASDAQ: RCEL), una empresa de medicina regenerativa especializada en el manejo de heridas y dispositivos para la restauraci贸n de la piel, ha anunciado su participaci贸n en la 43陋 Conferencia Anual de Salud de J.P. Morgan. El CEO Jim Corbett 辫谤别蝉别苍迟补谤谩 el jueves 16 de enero de 2025, a las 9:00 a.m. hora del Pac铆fico. La presentaci贸n estar谩 disponible a trav茅s de una transmisi贸n en vivo de audio en el sitio web de relaciones con inversores de la empresa, con una opci贸n de repetici贸n disponible despu茅s de que finalice el evento.
AVITA Medical (NASDAQ: RCEL)電� 靸侅矘 甏�毽� 氚� 頂茧秬 氤奠洂 鞛ル箘毳� 鞝勲鞙茧 頃橂姅 鞛儩 鞚橅暀 須岇偓搿滌劀 鞝�43須� 鞐半 J.P. Morgan 項姢旒�鞏� 旎嵓霟办姢鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. CEO 歆� 旖旊ゴ氩�鞚赌 2025雲� 1鞗� 16鞚� 氇╈殧鞚� 鞓れ爠 9鞁�(韮滍弶鞏� 響滌鞁�)鞐� 氚滍憸毳� 歆勴枆頃� 鞓堨爼鞛呺媹雼�. 鞚� 氚滍憸電� 須岇偓鞚� 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 霛检澊敫� 鞓る敂鞓� 鞗轨簮鞀ろ姼搿� 鞝滉车霅橂┌, 頄夓偓 膦呺 頉勳棎電� 雼れ嫓 氤搓赴 鞓奠厴鞚� 鞝滉车霅╇媹雼�.
AVITA Medical (NASDAQ: RCEL), une entreprise de m茅decine r茅g茅n茅ratrice sp茅cialis茅e dans la gestion des plaies et les dispositifs de restauration de la peau, a annonc茅 sa participation 脿 la 43猫me Conf茅rence Annuelle J.P. Morgan sur la Sant茅. Le PDG Jim Corbett pr茅sentera le jeudi 16 janvier 2025, 脿 9h00, heure du Pacifique. La pr茅sentation sera disponible via un webinaire audio en direct sur le site des relations avec les investisseurs de l'entreprise, avec une option de rediffusion disponible apr猫s la fin de l'茅v茅nement.
AVITA Medical (NASDAQ: RCEL), ein Unternehmen f眉r regenerative Medizin, das auf das Wundmanagement und Hautrestaurationsger盲te spezialisiert ist, hat seine Teilnahme an der 43. J.P. Morgan Healthcare Conference bekannt gegeben. CEO Jim Corbett wird am Donnerstag, den 16. Januar 2025, um 9:00 Uhr Pazifischer Zeit eine Pr盲sentation halten. Die Pr盲sentation wird 眉ber einen Live-Audio-Webcast auf der Investor-Relations-Website des Unternehmens verf眉gbar sein, mit einer Wiederholungsoption nach Abschluss der Veranstaltung.
- None.
- None.
VALENCIA, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 9:00 a.m. Pacific Time.
A live audio webcast of the presentation will be accessible under the Events & Presentations section of the Company's website at . A replay of the webcast will be available following the conclusion of the event.
About AVITA Medical, Inc.
AVITA Medical庐 is a commercial-stage regenerative medicine company transforming the standard of care in wound care management and skin restoration with innovative devices. At the forefront of our platform is the RECELL庐 System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient鈥檚 own skin to create Spray-On Skin鈩� Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. In the United States, AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm庐, a biosynthetic wound matrix, and Cohealyx鈩�, an AVITA Medical-branded collagen-based dermal matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System, excluding RECELL GO鈩�, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.
To learn more, visit鈥�.
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
FAQ
When is AVITA Medical (RCEL) presenting at the J.P. Morgan Healthcare Conference 2025?
How can investors watch AVITA Medical's (RCEL) J.P. Morgan Healthcare Conference presentation?
What is AVITA Medical's (RCEL) business focus?
Who will represent AVITA Medical (RCEL) at the 2025 J.P. Morgan Healthcare Conference?
